Literature DB >> 23870425

CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.

Vyara Valkanova1, Klaus P Ebmeier, Charlotte L Allan.   

Abstract

BACKGROUND: Inflammatory markers are raised in cross-sectional studies of depressed patients and may represent an important mediating factor for behaviour, neural plasticity and brain structure.
METHODS: We undertook a systematic review of longitudinal studies, investigating whether raised inflammatory markers indicate an increased risk of subsequent depressive symptoms. We searched three databases (1970-2012) for longitudinal studies with repeat data on CRP or IL-6 levels and subsequent depressive symptoms. We calculated effect sizes using a mixed-effects model, with separate meta-analyses for inflammatory markers and age groups.
RESULTS: We identified eight papers for CRP (14,832 participants) and three for IL-6 (3695 participants). There was a significant association between increased CRP and depressive symptoms (weighted-mean effect size 'unadjusted r'=0.069, p<0.0005; 'adjusted r'=0.046, p<0.0005), with moderate heterogeneity between studies (Q=11.21, p=0.08, I(2)=46.5). For IL-6 the weighted-mean effect size was smaller ('unadjusted r'=0.045, p-value=0.007; 'adjusted r'=0.097, p-value=0.06). LIMITATIONS: The meta-analysis was based on a relatively small number of studies (particularly for IL-6) and only two inflammatory markers. There was moderate heterogeneity between studies and some evidence of publication bias.
CONCLUSIONS: Raised inflammatory markers have a small but significant association with the subsequent development of depressive symptoms. This is a robust effect which remains significant after adjustment for age and a wide range of factors associated with risk for depression. Our results support the hypothesis that there is a causal pathway from inflammation to depression.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRP; Depressive; IL-6; Inflammation; Longitudinal; Meta-analysis

Mesh:

Substances:

Year:  2013        PMID: 23870425     DOI: 10.1016/j.jad.2013.06.004

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  275 in total

1.  Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior.

Authors:  Elisabeth G Vichaya; Phillip S Gross; Darlene J Estrada; Steve W Cole; Aaron J Grossberg; Scott E Evans; Michael J Tuvim; Burton F Dickey; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530

Review 2.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

3.  Adjustment disorder and risk of Parkinson's disease.

Authors:  E Svensson; D K Farkas; J L Gradus; T L Lash; H T Sørensen
Journal:  Eur J Neurol       Date:  2016-01-12       Impact factor: 6.089

Review 4.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

5.  A Functional Interleukin-18 Haplotype Predicts Depression and Anxiety through Increased Threat-Related Amygdala Reactivity in Women but Not Men.

Authors:  Johnna R Swartz; Aric A Prather; Christina R Di Iorio; Ryan Bogdan; Ahmad R Hariri
Journal:  Neuropsychopharmacology       Date:  2016-07-19       Impact factor: 7.853

Review 6.  Sex Differences in Depression: Does Inflammation Play a Role?

Authors:  Heather M Derry; Avelina C Padin; Jennifer L Kuo; Spenser Hughes; Janice K Kiecolt-Glaser
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

7.  Longitudinal association of inflammation with depressive symptoms: A 7-year cross-lagged twin difference study.

Authors:  Minxuan Huang; Shaoyong Su; Jack Goldberg; Andrew H Miller; Oleksiy M Levantsevych; Lucy Shallenberger; Pratik Pimple; Bradley Pearce; J Douglas Bremner; Viola Vaccarino
Journal:  Brain Behav Immun       Date:  2018-10-27       Impact factor: 7.217

8.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

9.  Social isolation after stroke leads to depressive-like behavior and decreased BDNF levels in mice.

Authors:  Lena M O'Keefe; Sarah J Doran; Laetitia Mwilambwe-Tshilobo; Lisa H Conti; Venugopal R Venna; Louise D McCullough
Journal:  Behav Brain Res       Date:  2013-11-05       Impact factor: 3.332

10.  An Association Between the Inflammatory Biomarker GlycA and Depressive Symptom Severity.

Authors:  Samara Huckvale; Stephanie Reyes; Alexandra Kulikova; Anand Rohatgi; Kayla A Riggs; E Sherwood Brown
Journal:  J Clin Psychiatry       Date:  2020-11-17       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.